Navigation Links
New knowledge about the brain's effective bouncer
Date:7/15/2014

Research from the University of Copenhagen is shedding new light on the brain's complicated barrier tissue. The blood-brain barrier is an effective barrier which protects the brain, but which at the same time makes it difficult to treat diseases such as Alzheimer's. In an in vitro blood-brain barrier, researchers can recreate the brain's transport processes for the benefit of the development of new pharmaceuticals for the brain. The new research findings are published in the AAPS Journal.

Ninety-five per cent of all tested pharmacological agents for treating brain disorders fail, because they cannot cross the blood-brain barrier. It is therefore important to find a possible method for transporting drugs past the brain's efficient outpost and fervent protector.

Researchers at the Department of Pharmacy at the University of Copenhagen have recreated the complex blood-brain barrier in a laboratory model, which is based on cells from animals. In a new study, the researchers have studied the obstreperous bouncer proteins in the barrier tissue. The proteins protect the brain, but also prevent the treatment of brain diseases:

"The blood-brain barrier is chemically tight because the cells contain transporter proteins which make sure that substances entering the cells are thrown straight back out into the bloodstream again. We have shown that the barrier which we have created in the laboratory contains the same bouncer proteins and that they behave in the same way as in a 'real' brain. This is important, because the model can be used to test drive the difficult way into the brain. Complex phenomena which we have so far only been able to study in live animals can now be investigated in simple laboratory experiments using cultivated cells," says postdoc Hans Christian Cederberg Helms from the Department of Pharmacy.

The research team has shown that the transporter proteins P-glycoprotein, breast cancer resistance protein and
'/>"/>

Contact: Birger Brodin
birger.brodin@sund.ku.dk
45-22-48-03-55
University of Copenhagen The Faculty of Health and Medical Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers uncover new knowledge about our intestines
2. Architecture of signaling proteins enhances knowledge of key receptors
3. Canadian physicians lack knowledge and confidence about breastfeeding
4. New atom-scale knowledge on the function of biological photosensors
5. Thousands of new particles in workplaces despite large knowledge gap
6. New knowledge about serious muscle disease
7. Knowledge about incontinence and pelvic organ prolapse lower among women of color
8. Reproductive biologists move in vitro fertilization knowledge forward
9. New framework to deliver biodiversity knowledge
10. New knowledge about permafrost improving climate models
11. Ag, big data, and traditional knowledge headline the Ecological Society of Americas 2013 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... plate may soon take on a literal meaning. Diane Bisson, ... Design, has fashioned edible plates that are practical, stylish and ... which has resulted in a book highlighting more than 50 ... Material. "The idea of using food to support a ...
... of Georgia scientists looking to understand the genetic mechanisms ... first time in plants an inverse relationship between gene ... diversity not only in plants, but in animals and ... this week,s Proceedings of the National Academy of ...
... , , TORONTO, Dec. 7 ... acquired the assets of the healthcare communications company previously operating ... now move forward under new leadership and funding. , IgeaCare ... of Chief Executive Officer. Under his direction, the new company ...
Cached Biology News:Plate-eating good: Université de Montréal professor designs edible tableware 2Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2
(Date:5/21/2015)... -- Prima Biomed Ltd. (NASDAQ: PBMD ) a globally ... leader in the development of immunotherapeutic products for the ... data from the Phase II CAN-003 ovarian cancer clinical ... meaningful improvement in Overall Survival ("OS") over standard of ... the group of second remission patients (n=20), the median ...
(Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
(Date:5/20/2015)... Calif. , May 20, 2015 ... today presented preliminary data demonstrating the ability of ... pulmonary fibrosis (IPF) from other interstitial lung diseases ... suggest the classifier,s potential to help thousands of ... resolve ambiguity in IPF diagnosis – a frequent ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Global Survey on Flow Cytometry Adoption Trends 2015 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... today announced the filing of its audited,consolidated financial ... ended December 31, 2007 and the restatement of ... December 31, 2006., For the year ended ...
... Calif., March 13 Bionovo, Inc.,(Nasdaq: BNVI ... Ph.D., to,the company,s Board of Directors. Dr. Butler ... and in particular in,advancing cancer drug development and ... have George on board as we move into ...
... LEUVEN, Belgium, March 13 ThromboGenics NV,(Euronext Brussels: ... announces a business update and its financial results ... During this period,ThromboGenics has raised additional funds to ... make good progress with its clinical,programs., Highlights, ...
Cached Biology Technology:Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 2Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 3Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 4Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 5Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 6Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 7Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 8Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 9George Butler Joins Bionovo's Board of Directors 2George Butler Joins Bionovo's Board of Directors 3ThromboGenics Announces 2007 Full Year Results 2ThromboGenics Announces 2007 Full Year Results 3ThromboGenics Announces 2007 Full Year Results 4
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
... kit for 25 chips provides the chips ... analysis (at picogram levels) with the Experion ... RNA HighSens microfluidic chips, 2 x 1,250 ... RNA HighSens stain, 20 microliters RNA ladder, ...
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
... kit provides all the accessories necessary for ... conformation polymorphism analysis (SSCP) with the DCode ... a cooling finger adaptor for use with ... of 20 cm plates, 2 sets of ...
Biology Products: